Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.52 EUR | -1.50% | -14.02% | -6.19% |
05-15 | Barclays lowers Schott Pharma target to 25 euros - 'Equal Weight' | DP |
05-15 | SCHOTT PHARMA : Deutsche Bank reiterates its Buy rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 32.01 and 26.6 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.19% | 5.16B | - | ||
-5.43% | 181B | C+ | ||
+4.30% | 114B | C | ||
-3.09% | 68.29B | A | ||
+5.86% | 52.24B | B- | ||
+8.15% | 44.3B | B- | ||
+7.52% | 42.73B | B+ | ||
+25.54% | 32.52B | B | ||
+17.85% | 26.02B | A- | ||
+1.00% | 25.91B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1SXP Stock
- Ratings SCHOTT Pharma AG & Co. KGaA